Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Introduces First Cryo-electron Microscopy System in Pharmaceutical Industry in Japan

05/30/2021 | 10:36pm EDT

Chugai Introduces First Cryo-electron Microscopy System in

Pharmaceutical Industry in Japan

  • Chugai introduced a cryo-electron microscopy system for the first time in the Japanese pharmaceutical industry. It aims to increase the probability of success through realizing a more precise molecular design based on structural analysis of drug candidate compounds
  • Chugai aims to accelerate drug discovery research in various fields including mid-size molecule drugs, small molecules, and antibodies

TOKYO, May 31, 2021 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced its introduction of the first cryo-electron microscopy (Cryo-EM) system in the Japanese pharmaceutical industry to further accelerate drug discovery research.

The cryo-EM, for which the Nobel Prize in Chemistry 2017 was awarded, has been drawing attentions as an innovative technology. The system was introduced for the structural analysis of drug candidate molecules bound to target proteins, which is an essential process in drug discovery research.

Chugai places great emphasis on Structure-Based Drug Design in its drug discovery research, and aims to create quality drug candidate compounds by pursuing precise structure design. X-ray crystallographic analysis, which we have primarily used to obtain molecular structure, requires crystallization of the intracellular protein which a drug candidate targets. The mid-size molecule drug which Chugai focuses on mainly targets such proteins that are difficult to crystallize, which has posed a challenge in the refinement of compound design.

As the cryo-EM does not require the crystallization process, it enables structure analysis of a wider range of molecules including intracellular proteins that are difficult to crystallize, as well as significantly improving research efficiency. We hope that it will enhance our Structure Based Drug Design capability and increase the success rate of compound development. This system we introduced is provided by Thermo Fisher Scientific, and installed at Kamakura research laboratories for the structural analysis of a variety of drug candidate compounds including mid-size molecule drugs.

"The introduction of cryo-EM is expected to greatly transform Chugai's drug discovery process. It will further enhance the quality and speed of Structure Based Drug Design, and accelerate the discovery of mid-size molecule drugs which we aim to establish as the third modality," said Dr. Osamu Okuda, Chugai's President and CEO. "Chugai's drug discovery is supported by its unique scientific and technological capabilities. We will continue to rigorously adopt advanced technologies to realize innovations that contribute to resolve unmet medical needs."

About cryo electron microscopy (Cryo-EM)

Cryo-electron microscopy (Cryo-EM) is a powerful biophysical technique that allows researchers to visualize molecular assemblies at near-atomic resolution. With the rapid technological advancements, structural elucidation of biological molecules such as protein has been rapidly increased, in particular for intractable biological molecules by existing methods such as X-ray crystallography and NMR technique.

Cryo-EM has been recently applied in the pharmaceutical industry around the world due to its ability to accurately and rapidly visualize the intricate interactions between drug and receptor, enabling informed, accelerated drug discovery and structure based drug design.

###

2 / 2

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 31 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 May 2021 02:35:01 UTC.


© Publicnow 2021
All news about CHUGAI PHARMACEUTICAL CO., LTD.
09/15PRESS RELEASE : Roche opens access to pathology imaging tools to improve patient..
DJ
09/14PRESS RELEASE : Temedica develops new digital companion Brisa for people with mu..
DJ
09/13CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
09/09PRESS RELEASE : Roche signs definitive share purchase agreement with long-term p..
DJ
09/08Nikkei 225 Up 0.9%, Tops 30,000, Extends Rally on New Government Hopes
MT
09/08Japan's Nikkei ends at near 6-month high on bargain hunting for cheap stocks
RE
09/07PRESS RELEASE : Roche to present data from -2-
DJ
08/30Nikkei 225 Gains 0.5% on Wall Street Cues, Softer Yen
MT
08/30CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
08/27PRESS RELEASE : Roche provides update on Tecentriq -2-
DJ
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD.
More recommendations
Financials
Sales 2021 880 B 8 045 M 8 045 M
Net income 2021 264 B 2 413 M 2 413 M
Net cash 2021 485 B 4 436 M 4 436 M
P/E ratio 2021 26,0x
Yield 2021 1,45%
Capitalization 6 853 B 62 646 M 62 637 M
EV / Sales 2021 7,23x
EV / Sales 2022 7,22x
Nbr of Employees 7 555
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 4 168,00 JPY
Average target price 4 696,92 JPY
Spread / Average Target 12,7%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-24.26%62 646
JOHNSON & JOHNSON5.11%435 465
ROCHE HOLDING AG11.23%327 497
PFIZER, INC.21.46%251 011
NOVO NORDISK A/S49.16%231 607
ELI LILLY AND COMPANY38.43%211 895